NEPTUNUS LISTING IN AUSTRALIA
Chinese company Neptunus Pharmaceuticals is to seek a listing on the Australian Stock Exchange with an estimated A$50 million ($36.25 million) stock offer.
According to Ray Schoer, national director of operations at the Australian Stock Exchange, there have been a number of meetings with the China Agribusiness Development Trust and Investment Corp, Neptunus Pharmaceuticals' parent company, over the intending listing, which may include a number of its other subsidiaries. However, the main approach is from Neptunus, which is set to become only the second Chinese company to list in Australia after Gunadong Corp, which uses Melbourne as its home exchange. However, Neptunus is expected to use Sydney as its home base.
Mr Schoer said that there would be a great deal of interest in Australia for listings of these types, especially among the Asian investment institutions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze